No connection

Search Results

ALUR vs BMRA

ALUR
Allurion Technologies Inc.
BEARISH
Price
$0.53
Market Cap
$7.9M
Sector
Healthcare
AI Confidence
85%
BMRA
Biomerica, Inc.
BEARISH
Price
$2.57
Market Cap
$7.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ALUR
--
BMRA
--
Forward P/E
ALUR
-1.1
BMRA
6.59
P/B Ratio
ALUR
-0.05
BMRA
1.71
P/S Ratio
ALUR
0.46
BMRA
1.74
EV/EBITDA
ALUR
-2.12
BMRA
-1.06

Profitability

Gross Margin
ALUR
60.99%
BMRA
5.63%
Operating Margin
ALUR
-362.3%
BMRA
-113.47%
Profit Margin
ALUR
-187.87%
BMRA
-90.31%
ROE
ALUR
--
BMRA
-84.3%
ROA
ALUR
-71.87%
BMRA
-49.44%

Growth

Revenue Growth
ALUR
-50.5%
BMRA
-26.0%
Earnings Growth
ALUR
--
BMRA
--

Financial Health

Debt/Equity
ALUR
--
BMRA
0.06
Current Ratio
ALUR
1.26
BMRA
3.25
Quick Ratio
ALUR
0.87
BMRA
2.18

Dividends

Dividend Yield
ALUR
--
BMRA
--
Payout Ratio
ALUR
0.0%
BMRA
0.0%

AI Verdict

ALUR BEARISH

ALUR exhibits severe financial distress with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability, collapsing revenue growth, and negative ROA (-71.87%) signal high distress risk. Despite a gross margin of 60.99%, the company is losing money at an accelerating rate, with a -187.87% profit margin and -362.30% operating margin. The stock trades at a deeply discounted price of $0.53, but this reflects a market pricing in failure rather than value. Analysts have a target of $5.50, but with no consensus recommendation and a 5-year return of -99.8%, the outlook remains bleak.

Strengths
Gross margin of 60.99% indicates strong product-level pricing power or cost control
Recent quarterly earnings have shown positive surprises (avg +25.09%) in the last four quarters
Insider activity, though bearish, is minimal (only one sale in 6 months)
Risks
Piotroski F-Score of 0/9 indicates severe financial deterioration and operational failure
Revenue declined 50.5% YoY, signaling a collapsing business model
Negative ROA (-71.87%) and negative operating margin (-362.30%) reflect deep operational inefficiency
BMRA BEARISH

The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.

Strengths
Low Debt/Equity ratio of 0.06 suggests minimal leverage risk
Current Ratio of 3.25 indicates strong short-term liquidity
Quick Ratio of 2.18 supports near-term financial flexibility
Risks
Piotroski F-Score of 1/9 signals critical weakness in earnings, leverage, and operating efficiency
Profit margin of -90.31% and operating margin of -113.47% reflect severe unprofitability
Revenue growth down 26% YoY, indicating shrinking top line and possible market rejection

Compare Another Pair

ALUR vs BMRA: Head-to-Head Comparison

This page compares Allurion Technologies Inc. (ALUR) and Biomerica, Inc. (BMRA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile